Cancer
Malignant Central Nervous System Neoplasm
CI-CAN-00001115Explore in graph →
Top-level823 active trials5 approved drugs103 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001115Explore in graph →
Clinical trials
2,866 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (418)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05131022 | A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | recruiting | Phase 1 | 572 | Nurix Therapeutics, Inc.INDUSTRY | 8 | Jul 2, 2026 | clinicaltrials |
| NCT07118176 | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers | active not recruiting | Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT03655223 | Early Check: Expanded Screening in Newborns | active not recruiting | — | 30,000 | RTI InternationalOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04195555 | Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 3 | Jul 1, 2026 | clinicaltrials |
| NCT04416568 | Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers | active not recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05698199 | Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM) | completed | Phase 1 | 10 | Immunomic Therapeutics, Inc.INDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05720078 | UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-3 (UNITED-3)(UNITED-3) | active not recruiting | N/A | 70 | Sunnybrook Health Sciences CentreOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06061809 | N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma | active not recruiting | Phase 2 | 34 | ImmunityBio, Inc.INDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06388733 | A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma | active not recruiting | Phase 3 | 450 | Ivy Brain Tumor CenterOTHER | 11 | Jul 1, 2026 | clinicaltrials |
| NCT06455189 | Magnetic Resonance Fingerprinting Guided Extended Resection in Glioblastomas | withdrawn | Phase 1 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06665373 | Fitness and Nutrition in Glioma | active not recruiting | N/A | 15 | NYU Langone HealthOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06805305 | DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) | recruiting | Phase 2 | 180 | Diakonos Oncology CorporationINDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07210632 | Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG) | recruiting | Early Phase 1 | 38 | Eben RosenthalOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07674095 | Assessment of a Large US EHR Database as Meeting FDA Fit-for-Purpose Requirements to Provide External Controls for Study BPM31510 in Participants With Glioblastoma | active not recruiting | — | 150 | BPGbioINDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07678138 | Exploratory Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247, Beijing YSCell Biotech Co., Ltd. [Abbreviated as YS])in Patients With Recurrent or Progressive Glioblastoma | not yet recruiting | N/A | 9 | Huanhu Hospital Affiliated to Tianjin Medical UniversityOTHER | 0 | Jul 1, 2026 | clinicaltrials |
| NCT05864976 | Neurosurgical Neuronavigation Using Resting State MRI and Machine Learning | recruiting | — | 100 | Washington University School of MedicineOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT06169280 | Repeated Neural Stem Cell Based Virotherapy for Newly Diagnosed High Grade Glioma | suspended | Phase 1 | 20 | Northwestern UniversityOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07493447 | Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures | recruiting | Early Phase 1 | 30 | Eben RosenthalOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07670455 | Brain Radiotherapy Imaging for High-grade Glioma Using Hypoxia Targeting Through Oxygen-Enhanced Response(BRIGHTER) | not yet recruiting | N/A | 25 | The Leeds Teaching Hospitals NHS TrustOTHER | 0 | Jun 30, 2026 | clinicaltrials |
| NCT01783535 | Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma | active not recruiting | Phase 2 | 174 | St. Jude Children's Research HospitalOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT02012699 | Integrated Cancer Repository for Cancer Research(iCaRe2) | recruiting | — | 999,999 | University of NebraskaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT02177578 | Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme | active not recruiting | Phase 2 | 60 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT03510208 | Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery | recruiting | Phase 1 / Phase 2 | 46 | Stanford UniversityOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05326464 | Tofacitinib in Recurrent GBM Patients | completed | Phase 3 | 18 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05627323 | CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma | terminated | Phase 1 | 1 | Chimeric TherapeuticsINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06333899 | Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion | recruiting | Early Phase 1 | 15 | Nationwide Children's HospitalOTHER | 6 | Jun 29, 2026 | clinicaltrials |
| NCT06815029 | Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma | recruiting | Phase 1 | 27 | City of Hope Medical CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06861244 | Embryonal Tumor With Multilayered Rosettes(PNOC031) | recruiting | Phase 2 | 70 | University of California, San FranciscoOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07284628 | Vortioxetine for Newly Diagnosed Glioblastoma(ReVoGlio) | recruiting | Phase 2 | 78 | University of ZurichOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07673666 | GliomaAI-Astro23: MRI-Based Detection of IDH Mutant Astrocytoma (Grade 2 and 3)(GliomaAI-A23) | completed | — | 1,372 | Deep Learning Institute of Radiological SciencesOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07673679 | GliomaAI-Astro4: MRI-Based Detection of IDH Mutant Astrocytoma Grade 4(GliomaAI-A4) | completed | — | 1,372 | Deep Learning Institute of Radiological SciencesOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07674693 | Phase 1 Study of WBRT or PCSI With REYOBIQ for Leptomeningeal Metastases | not yet recruiting | Phase 1 | 29 | NYU Langone HealthOTHER | 0 | Jun 29, 2026 | clinicaltrials |
| NCT00209989 | Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme | completed | Phase 2 | 27 | Institut Claudius RegaudOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT02303678 | D2C7 for Adult Patients With Recurrent Malignant Glioma | completed | Phase 1 | 81 | Darell BignerOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT05009992 | Combination Therapy for the Treatment of Diffuse Midline Gliomas(PNOC022) | recruiting | Phase 2 | 360 | University of California, San FranciscoOTHER | 6 | Jun 26, 2026 | clinicaltrials |
| NCT05120284 | Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM) | active not recruiting | Phase 2 | 40 | University of FloridaOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT06157541 | T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma(TCaP) | active not recruiting | Phase 1 / Phase 2 | 58 | Queensland Institute of Medical ResearchOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07198087 | A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants | completed | Phase 1 | 40 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 26, 2026 | clinicaltrials |
| NCT03175432 | Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases | active not recruiting | Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04573140 | A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)(PNOC020) | recruiting | Phase 1 | 28 | University of FloridaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07668869 | TTFields Plus FET-PET-Guided Stereotactic Radiosurgery Versus TTFields Alone for Recurrent Glioblastoma (Tarrget 2.0) | recruiting | N/A | 92 | Prof. Franciszek Lukaszczyk Memorial Oncology CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07670026 | Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term Progression | recruiting | Phase 2 | 31 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07468136 | Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas | recruiting | Phase 1 / Phase 2 | 33 | Mayo ClinicOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07664579 | Investigating the Feasibility and Acceptability of an Innovative Interdisciplinary Supportive Care Program: Couples Coping Together Against Cancer | recruiting | — | 160 | City of Hope Medical CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT04225039 | Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma | active not recruiting | Phase 2 | 39 | University of PennsylvaniaOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04678648 | A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies | recruiting | Phase 1 | 134 | RasCal Therapeutics, Inc.INDUSTRY | 1 | Jun 23, 2026 | clinicaltrials |
| NCT05590689 | Radiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Brain Tumor(ALA-RDTinGBM) | recruiting | Phase 1 / Phase 2 | 34 | Universität MünsterOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07387666 | Imaging Acetadote Metabolism in Glioblastoma | recruiting | Early Phase 1 | 10 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07447076 | Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT) | recruiting | Phase 2 | 29 | Sabine Mueller, MD, PhDOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03277729 | A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | active not recruiting | Phase 1 / Phase 2 | 53 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jul 2, 2026source: clinicaltrials